http://orcid.org/0000-0001-7939-7204
Citations (27)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Gabriela D. Colpo, Marion Leboyer, Robert Dantzer, Mahdukar H. Trivedi & Antonio L. Teixeira. (2018) Immune-based strategies for mood disorders: facts and challenges. Expert Review of Neurotherapeutics 18:2, pages 139-152.
Read now
Read now
Articles from other publishers (26)
Hyunjin Shin, Hyun Goo Woo, Kyung-Ah Sohn & Sungjoo Lee. (2023) Comparing research trends with patenting activities in the biomedical sector: The case of dementia. Technological Forecasting and Social Change 195, pages 122790.
Crossref
Crossref
Ryo Okuyama. (2023) Advancements in Drug Repurposing: Examples in Psychiatric Medications. International Journal of Molecular Sciences 24:13, pages 11000.
Crossref
Crossref
I. I. Miroshnichenko, E. A. Valdman & I. I. Kuz'min. (2023) Old Drugs, New Indications (Review). Drug development & registration 12:1, pages 182-190.
Crossref
Crossref
Tiffany Schwasinger-Schmidt & Sheldon H. Preskorn. 2023. Drug Development in Psychiatry. Drug Development in Psychiatry
195
206
.
Pierpaolo Andriani & Gino Cattani. (2022) Functional diversification and exaptation: the emergence of new drug uses in the pharma industry. Industrial and Corporate Change 31:5, pages 1177-1201.
Crossref
Crossref
Trang T. T. Truong, Bruna Panizzutti, Jee Hyun Kim & Ken Walder. (2022) Repurposing Drugs via Network Analysis: Opportunities for Psychiatric Disorders. Pharmaceutics 14:7, pages 1464.
Crossref
Crossref
Gilbert Giacomoni. (2022) Towards a general framework for innovation shaped with AI to create and transform market offerings. European Management Review 19:1, pages 107-122.
Crossref
Crossref
Małgorzata Jarończyk & Jarosław Walory. (2022) Novel Molecular Targets of Antidepressants. Molecules 27:2, pages 533.
Crossref
Crossref
Sibren van den Berg, Saco de Visser, Hubert G.M. Leufkens & Carla E.M. Hollak. (2021) Drug Repurposing for Rare Diseases: A Role for Academia. Frontiers in Pharmacology 12.
Crossref
Crossref
Stefania Demuro, Rita M. C. Di Martino, Jose A. Ortega & Andrea Cavalli. (2021) GSK-3β, FYN, and DYRK1A: Master Regulators in Neurodegenerative Pathways. International Journal of Molecular Sciences 22:16, pages 9098.
Crossref
Crossref
Maria Gogou & J Helen Cross. (2021) Fenfluramine as antiseizure medication for epilepsy. Developmental Medicine & Child Neurology 63:8, pages 899-907.
Crossref
Crossref
Hosna Mohammad Sadeghi, Ida Adeli, Taraneh Mousavi, Marzieh Daniali, Shekoufeh Nikfar & Mohammad Abdollahi. (2021) Drug Repurposing for the Management of Depression: Where Do We Stand Currently?. Life 11:8, pages 774.
Crossref
Crossref
Adriano José Maia Chaves Filho, Melina Mottin, Michele Verde-Ramo Soares, Paloma Marinho Jucá, Carolina Horta Andrade & Danielle S. Macedo. (2021) Tetracyclines, a promise for neuropsychiatric disorders: from adjunctive therapy to the discovery of new targets for rational drug design in psychiatry. Behavioural Pharmacology 32:2&3, pages 123-141.
Crossref
Crossref
Rammohan Shukla, Nicholas D. Henkel, Khaled Alganem, Abdul-rizaq Hamoud, James Reigle, Rawan S. Alnafisah, Hunter M. Eby, Ali S. Imami, Justin F Creeden, Scott A. Miruzzi, Jaroslaw Meller & Robert E. Mccullumsmith. (2020) Signature-based approaches for informed drug repurposing: targeting CNS disorders. Neuropsychopharmacology 46:1, pages 116-130.
Crossref
Crossref
Márcia Martins, Renata Silva, Madalena M. M. Pinto & Emília Sousa. (2020) Marine Natural Products, Multitarget Therapy and Repurposed Agents in Alzheimer’s Disease. Pharmaceuticals 13:9, pages 242.
Crossref
Crossref
Yoichi Morofuji & Shinsuke Nakagawa. (2020) Drug Development for Central Nervous System Diseases Using In vitro Blood-brain Barrier Models and Drug Repositioning. Current Pharmaceutical Design 26:13, pages 1466-1485.
Crossref
Crossref
Alexander E Clout, Oscar Della Pasqua, Michael G Hanna, Mine Orlu & Robert D S Pitceathly. (2019) Drug repurposing in neurological diseases: an integrated approach to reduce trial and error. Journal of Neurology, Neurosurgery & Psychiatry 90:11, pages 1270-1275.
Crossref
Crossref
Ebrahim M. Yimer, Hailemichael Zeru Hishe & Kald Beshir Tuem. (2019) Repurposing of the β-Lactam Antibiotic, Ceftriaxone for Neurological Disorders: A Review. Frontiers in Neuroscience 13.
Crossref
Crossref
Santiago G. Lago & Sabine Bahn. (2018) Clinical Trials and Therapeutic Rationale for Drug Repurposing in Schizophrenia. ACS Chemical Neuroscience 10:1, pages 58-78.
Crossref
Crossref
Pawan Kumar & Indira Ghosh. 2019. In Silico Drug Design. In Silico Drug Design
427
462
.
Jonathan Posner. (2018) The Role of Precision Medicine in Child Psychiatry: What Can We Expect and When?. Journal of the American Academy of Child & Adolescent Psychiatry 57:11, pages 813-817.
Crossref
Crossref
Charles K. Davis, Sreekala S. Nampoothiri & G. K. Rajanikant. (2018) Folic Acid Exerts Post-Ischemic Neuroprotection In Vitro Through HIF-1α Stabilization. Molecular Neurobiology 55:11, pages 8328-8345.
Crossref
Crossref
Christian Antonio Tuwahatu, Chi Chung Yeung, Yun Wah Lam & Vellaisamy Arul Lenus Roy. (2018) The molecularly imprinted polymer essentials: curation of anticancer, ophthalmic, and projected gene therapy drug delivery systems. Journal of Controlled Release 287, pages 24-34.
Crossref
Crossref
Maurizio Fava. (2018) The promise and challenges of drug repurposing in psychiatry. World Psychiatry 17:1, pages 28-29.
Crossref
Crossref
Hermann A. M. Mucke. (2017) Drug Repositioning in the Mirror of Patenting: Surveying and Mining Uncharted Territory. Frontiers in Pharmacology 8.
Crossref
Crossref
Mohamed Elsaed Ebada. (2017) Drug repurposing may generate novel approaches to treating depression. Journal of Pharmacy and Pharmacology 69:11, pages 1428-1436.
Crossref
Crossref